Home / Companies / Fisiopharma
Company family
Fisiopharma: medicine shortages
As of 2 Nov 2026, 8 Fisiopharma products have a reported shortage across 1 countries, covering 6 medicines.
Products short8rank #221 of 464
Medicines6active ingredients
Countries1/16
New in 90 days00 vs market pace
Typical duration2.6 yearsmedian so far
Manufacturing62%demand-driven 0%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Erythromycin | 2 | 22 Dec 2026 | Manufacturing problem | 10/16 | |
| Tobramycin | 2 | 12 Apr 2023 | Manufacturing problem | 5/16 | |
| Chloramphenicol | 1 | 28 Mar 2023 | Manufacturing problem | 2/16 | |
| Dobutamine | 1 | 30 Nov 2024 | Distribution or logistics | 5/16 | |
| Furosemide | 1 | 10 Oct 2025 | Commercial decision or withdrawal | 11/16 | |
| Lidocaine | 1 | 11 Apr 2025 | Commercial decision or withdrawal | 9/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.